UK Companies House feature
PHARMARON BIOLOGICS (UK) LTD
Cash
£12M
+6.6% vs 2023
Net assets
—
Equity attributable
Employees
187
+2.2% vs 2023
Profit before tax
-£311K
+68.9% vs 2023
Profile
- Company number
- 04543737
- Status
- Active
- Incorporation
- 2002-09-24
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Profit before tax
3-year trend · vs UK Healthcare median
Accounts
3-year trend · latest 2024-12-31
| Metric | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Turnover | — | — | — | |
| Operating profit | — | — | — | |
| Profit before tax | — | -£1,001,087 | -£311,147 | |
| Net profit | — | — | — | |
| Cash | — | £11,097,343 | £11,831,577 | |
| Total assets less current liabilities | — | — | — | |
| Net assets | — | — | — | |
| Equity | £21,919,695 | £59,879,869 | £75,742,104 | |
| Average employees | — | 183 | 187 | |
| Wages | — | £11,481,476 | £11,235,855 |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“The directors believe that preparing the financial statements on the going concern basis is appropriate. Forecasts prepared on the basis of the current costs model show that the Company will need financial support from its ultimate parent, Pharmaron. The directors have received a letter of support from Pharmaron for a period of 12 months from the date of approval of these financial statements in order to ensure that the Company can meet its obligations as they fall due.”
Significant events
- “The Company continued to make significant investment in capital assets during 2024 to replace end of life systems and develop innovative technologies to remain competitive in the marketplace and comply with UK and global regulatory standards.”
- “The Company continued its ambitious £89.3m, 8,000m2 expansion project on site in Liverpool.”
- “The building shell was completed May 2025.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| LEWINTON, Stephen | Secretary | 2021-04-30 | — | — |
| LEWINTON, Stephen Christopher, Mr. | Director | 2021-10-26 | Apr 1966 | British |
| LOU, Boliang, Dr | Director | 2021-04-30 | Sep 1963 | American |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BATE, Anita Susan | Secretary | 2004-06-01 | 2010-01-28 |
| HARAN, Patricia Maria | Secretary | 2018-02-19 | 2021-04-30 |
| NELLIGAN, Tom | Secretary | 2015-11-03 | 2017-10-13 |
| ROTHWELL, Neil Julian | Secretary | 2002-11-12 | 2004-06-01 |
| TOMKINS, Judith | Secretary | 2018-02-19 | 2020-10-02 |
| HALLIWELLS SECRETARIES LIMITED | Corporate Nominee Secretary | 2002-09-24 | 2002-11-12 |
| BISARO, Paul Mino | Director | 2010-01-28 | 2015-11-03 |
| BROWN, Crawford David, Dr | Director | 2002-11-12 | 2021-04-30 |
| BUCHEN, David Adam | Director | 2010-01-28 | 2015-05-01 |
| STEWART, Janice Elizabeth | Director | 2014-08-13 | 2017-06-30 |
| WILKINSON, Fred, Dr | Director | 2010-01-28 | 2014-04-25 |
| HALLIWELLS DIRECTORS LIMITED | Corporate Nominee Director | 2002-09-24 | 2002-11-12 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Pharmaron Beijing Co Ltd | Corporate entity | Shares 75–100% | 2021-04-30 | Ceased 2021-08-02 |
| Pharmaron Biologics (Uk) Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-04-30 | Active |
| Abbvie Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-05-08 | Ceased 2021-04-30 |
| Agn Sundry Llc | Corporate entity | Shares 75–100% | 2019-04-01 | Ceased 2019-04-01 |
| Allergan Plc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-05-31 | Ceased 2020-05-08 |
| Eden Biopharma Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2018-05-31 |
Filing timeline
Last 20 of 110 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2025-09-22 | AA | accounts | accounts with accounts type full |
| 2025-06-02 | CS01 | confirmation-statement | confirmation statement with updates |
| 2025-01-23 | RESOLUTIONS | resolution | resolution |
| 2025-01-22 | SH01 | capital | capital allotment shares |
| 2025-01-16 | RESOLUTIONS | resolution | resolution |
| 2024-07-04 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-06-03 | AA | accounts | accounts with accounts type full |
| 2023-09-22 | AA | accounts | accounts with accounts type full |
| 2023-07-18 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-02-09 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2022-10-06 | AA | accounts | accounts with accounts type full |
| 2022-07-21 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2021-10-27 | AP01 | officers | appoint person director company with name date |
| 2021-09-07 | AA | accounts | accounts with accounts type full |
| 2021-08-31 | CS01 | confirmation-statement | confirmation statement with updates |
| 2021-08-24 | PSC07 | persons-with-significant-control | cessation of a person with significant control |
| 2021-08-02 | PSC02 | persons-with-significant-control | notification of a person with significant control |
| 2021-05-14 | RESOLUTIONS | resolution | resolution |
| 2021-05-11 | PSC02 | persons-with-significant-control | notification of a person with significant control |
| 2021-05-11 | PSC07 | persons-with-significant-control | cessation of a person with significant control |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory